Founded in Baltimore in 2018, minority-owned BC3 Technologies develops and manufactures emergency bleeding-control products, including its FDA-cleared SEAL Hemostatic Wound Spray. The company makes and distributes its products in Maryland, drawing on a leadership team with 35 years of medical-device and drug-manufacturing experience and deep backgrounds in chemistry and emergency care.
FDA Clearance for SEAL Hemostatic Wound Spray
Minority-Owned Enterprise
Registration
CoagCo LLCCoagCo LLC develops bleeding-control medical devices, including the Coag it NP7 sterile nasal packing device for treating nosebleeds. Cleveland-based and co-founded by ENT physician Jeffrey E. Binder and attorney Tim Clements III, the company focuses on products that can help nurses, first responders, military medics and other providers control blood loss quickly. Its NP7 is made in America and designed for atraumatic insertion without local anesthesia.CLEVELAND, OH
ARMR Systems, IncARMR Systems engineers hemorrhage-control devices for moments when advanced medical help is out of reach, including its U.S.-made XT1 extremity tourniquet. The company’s broader focus is making trauma care more accessible through simple, portable systems that can be used at the point of injury, and its patented technology has been evaluated in clinical and operational settings. ARMR says its team has spent more than a decade developing solutions for both military and civilian emergencies.BALTIMORE, MD
ARC Trauma, LLCFounded in 2019, ARC Trauma is an Ohio medical-device company known for developing emergency equipment for use at the point of injury. Its work began with a team that brought together engineering and clinical experience to address life-threatening neck wounds, resulting in the FDA-approved Arterial Restriction Clamp for military and civilian care.JAMESTOWN, OH
Omni-stat Medical IncEstablished in 2018, Omni-stat Medical develops temporary topical hemostats for controlling bleeding in hospital and emergency-care settings. Its OMNI-STAT and CELOX products use proprietary chitosan granule technology, developed for wounds ranging from minor bleeding to severe arterial injuries and shown to work in the presence of common anticoagulants. The New York-based company is a subsidiary of Medtrade Products Limited and provides product training alongside its clinical solutions.New York, NY